Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10360134 | 0.87 | PTGDR2 (0.39) | LMNAPTGDR2GAAL3MBTL1POLB | |
| SCHEMBL3731990 | 0.84 | PTGDR2 (0.37) | LMNAPTGDR2GAAL3MBTL1POLB | |
| SCHEMBL9749252 | 0.83 | GAA (0.51) | LMNAPTGDR2GAAL3MBTL1POLB | |
| SCHEMBL10691191 | 0.83 | ALDH1A1 (0.40) | LMNAPTGDR2GAAL3MBTL1POLB | |
| SCHEMBL11120071 | 0.81 | GAA (0.36) | LMNAPTGDR2GAAL3MBTL1POLB | |
| SCHEMBL10794190 | 0.81 | ITGB3 (0.39) | LMNAGAAALDH1A1 | |
| SCHEMBL10689934 | 0.81 | LMNA (0.40) | LMNAGAAL3MBTL1POLBKDM4E | |
| SCHEMBL10688579 | 0.80 | LDHA (0.40) | PTGDR2GAAL3MBTL1POLBMAPT | |
| SCHEMBL10694025 | 0.80 | APEX1 (0.53) | GAAL3MBTL1POLBKDM4EALDH1A1 | |
| SCHEMBL10688546 | 0.79 | PPARA (0.43) | PTGDR2GAAL3MBTL1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4463173-A | ANTIBIOTIC, BACTERICIDE | ICI PHARMA (FR) | 1984-07-31 | — | — | US | claimed |
| EP-0031708-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES THEREFOR | ICI PHARMA (FR) | 1984-06-13 | — | — | EP | claimed |
| EP-1408093-B1 | COLORED IMAGE-FORMING COMPOSITIONS CONTAINING PHTHALOCYANINE COMPOUND, INKS, INKJET INKS, INKJET RECORDING METHOD AND METHOD OF IMPROVING TOLERANCE TO DECOLORATION DUE TO OZONE GAS | FUJIFILM CORP (JP) | 2018-02-21 | — | — | EP | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-1999041275-A1 | PRODRUGS | MEDIVIR AB (SE) | 1999-08-19 | — | — | WO | disclosed |
| EP-0346465-B1 | 1-CARBOXY-1-VYNILOXYIMINOAMINOTHIAZOLE CEPHALOSPORING DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-11 | — | — | EP | disclosed |
| US-5225406-A | Antibiotics | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| US-5084453-A | Antibiotics, bactericides | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-01-28 | — | — | US | disclosed |
| EP-0346465-A1 | 1-CARBOXY-1-VYNILOXYIMINOAMINOTHIAZOLE CEPHALOSPORING DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-12-20 | — | — | EP | disclosed |
| US-4762848-A | IMMUNE SYSTEM STIMULANTS, CYTOSTATIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-09 | — | — | US | disclosed |
| US-4463173-A | ANTIBIOTIC, BACTERICIDE | ICI PHARMA (FR) | 1984-07-31 | — | — | US | disclosed |
| EP-0031708-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES THEREFOR | ICI PHARMA (FR) | 1984-06-13 | — | — | EP | disclosed |
| EP-0031708-A2 | Cephalosporin derivatives, processes for their manufacture, pharmaceutical compositions containing them and intermediates therefor | ICI PHARMA (FR) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | LMNA 2948/4885PTGDR2 2337/4885GAA 520/4885 |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | LMNA 2948/4885PTGDR2 2337/4885GAA 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.